Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech director Kirti Ganorkar resigns from board, effective after December 31, 2025

Neutral Impact 2 of 5 leadership Written later

Krystal Biotech director Kirti Ganorkar gave notice on December 22, 2025 that he will resign from the Board. He will remain a director through December 31, 2025, and the company said the move was due to time constraints from his recent promotion at Sun Pharma, not a disagreement with the Board or management.

Key points

  • Kirti Ganorkar gave notice of resignation from the Board on December 22, 2025
  • He will continue as a director through December 31, 2025
  • Resignation attributed to time constraints from a recent promotion to Managing Director at Sun Pharma, not a disagreement with the company
  • He had served on the Board since the company's September 2017 initial public offering

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECDec 23, 2025, 4:51 PM ET
Accession number0001711279-25-000092

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 23, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.